Understanding the host genetics of chronic hepatitis B and C

Seminars in Liver Disease

Volumn 31, Issue 2, 2011, Pages 115-127

  Thursz, Mark ^a   Yee, Leland ^b   Khakoo, Salim ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

complex trait; genetic architecture; genetic susceptibility; Genome wide association study; interferon lambda

Indexed keywords

GAMMA INTERFERON; HEPATITIS B VACCINE; HLA B27 ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 28B; INTERLEUKIN 29; LYMPHOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA; WARFARIN;

ALLELE; ANTIVIRAL THERAPY; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; GENE LOCUS; GENETIC ASSOCIATION; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CANCER; NONHUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VACCINATION; VIRAL CLEARANCE; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERLEUKINS; LIVER CIRRHOSIS; LIVER NEOPLASMS; PATIENT SELECTION; PHENOTYPE; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS;

EID: 79955630080     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0031-1276642     Document Type: Article

References (106)

1. Lin T M., Chen C J., Wu M M. et al. Hepatitis B virus markers in Chinese twins. Anticancer Res 1989 9 3 737-741 (Pubitemid 19194309)
2. Thursz M. MHC and the viral hepatitides. QJM 2001 94 6 287-291 (Pubitemid 32600487)
3. Ferrari C, Penna A, Bertoletti A et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990 145 10 3442-3449
4. Chisari F V., Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995 13 29-60
5. Alper C A., Kruskall M S., Marcus-Bagley D et al. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989 321 11 708-712 (Pubitemid 19239702)
6. Caillat-Zucman S, Gimenez J J., Wambergue F et al. Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigen. Kidney Int 1998 53 6 1626-1630 (Pubitemid 28243745)
7. Hatae K, Kimura A, Okubo R et al. Genetic control of nonresponsiveness to hepatitis B virus vaccine by an extended HLA haplotype. Eur J Immunol 1992 22 7 1899-1905
8. Höhler T, Meyer C U., Notghi A et al. The influence of major histocompatability complex class II genes and T-cell Vbeta repertoire on response to immunization with HBsAg. Hum Immunol 1998 59 4 212-218 (Pubitemid 28176419)
9. McDermott A B., Zuckerman J N., Sabin C A., Marsh S G., Madrigal J A. Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination. Tissue Antigens 1997 50 1 8-14 (Pubitemid 27273706)
10. Thursz M R., Kwiatkowski D, Allsopp C EM, Greenwood B M., Thomas H C., Hill A VS. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med 1995 332 16 1065-1069
11. Höhler T, Gerken G, Notghi A et al. HLA-DRB1*1301 and*1302 protect against chronic hepatitis B. J Hepatol 1997 26 3 503-507 (Pubitemid 27112714)
12. Ahn S H., Han K H., Park J Y. et al. Association between hepatitis B virus infection and HLA-DR type in Korea. Hepatology 2000 31 6 1371-1373 (Pubitemid 30351301)
13. Almarri A, Batchelor J R. HLA and hepatitis B infection. Lancet 1994 344 8931 1194-1195 (Pubitemid 24323710)
14. Jiang Y G., Wang Y M., Liu T H., Liu J. Association between HLA class II gene and susceptibility or resistance to chronic hepatitis B. World J Gastroenterol 2003 9 10 2221-2225 (Pubitemid 37321449)
15. Milich D R., Leroux-Roels G G. Immunogenetics of the response to HBsAg vaccination. Autoimmun Rev 2003 2 5 248-257 (Pubitemid 37083491)
16. Thio C L., Carrington M, Marti D et al. Class II HLA alleles and hepatitis B virus persistence in African Americans. J Infect Dis 1999 179 4 1004-1006 (Pubitemid 29159348)
17. Meng X Q., Chen H G., Ma Y L., Liu K Z. Influence of HLA class II molecules on the outcome of hepatitis B virus infection in population of Zhejiang Province in China. Hepatobiliary Pancreat Dis Int 2003 2 2 230-233
18. Milich D R., Leroux-Roels G G., Louie R E., Chisari F V. Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg). IV. Distinct H-2-linked Ir genes control antibody responses to different HBsAg determinants on the same molecule and map to the I-A and I-C subregions. J Exp Med 1984 159 1 41-56 (Pubitemid 14182814)
19. Diepolder H M., Jung M C., Keller E et al. A vigorous virus-specific CD4 + T cell response may contribute to the association of HLA-DR13 with viral clearance in hepatitis B. Clin Exp Immunol 1998 113 2 244-251 (Pubitemid 28352843)
20. Davenport M P., Quinn C L., Valsasnini P, Sinigaglia F, Hill A V., Bell J I. Analysis of peptide-binding motifs for two disease associated HLA-DR13 alleles using an M13 phage display library. Immunology 1996 88 4 482-486 (Pubitemid 26255114)
21. Davenport M P., Quinn C L., Chicz R M. et al. Naturally processed peptides from two disease-resistance-associated HLA-DR13 alleles show related sequence motifs and the effects of the dimorphism at position 86 of the HLA-DR beta chain. Proc Natl Acad Sci U S A 1995 92 14 6567-6571
22. Thursz M R., Thomas H C., Greenwood B M., Hill A V. Heterozygote advantage for HLA class-II type in hepatitis B virus infection. [letter] [published erratum appears in Nat Genet 1998 Jan;18(1):88]. Nat Genet 1997 17 1 11-12
23. Thursz M, Yallop R, Goldin R, Trepo C, Thomas H C., Hepatitis C European Network for Cooperative Research. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Lancet 1999 354 9196 2119-2124 (Pubitemid 30008896)
24. Yee L J., Thursz M R. Hepatitis B and C. In: Kaslow R McNichol J Hill A V. Genetic Susceptibility in Infectious Disease. Oxford Oxford University Press 2007
25. Wawrzynowicz-Syczewska M, Underhill J A., Clare M A., Boron-Kaczmarska A, McFarlane I G., Donaldson P T. HLA class II genotypes associated with chronic hepatitis C virus infection and response to alpha-interferon treatment in Poland. Liver 2000 20 3 234-239 (Pubitemid 30342722)
26. Alric L, Fort M, Izopet J et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997 113 5 1675-1681 (Pubitemid 27461256)
27. Cramp M E., Carucci P, Underhill J, Naoumov N V., Williams R, Donaldson P T. Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. J Hepatol 1998 29 2 207-213 (Pubitemid 28352805)
28. Zavaglia C, Martinetti M, Silini E et al. Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C. J Hepatol 1998 28 1 1-7 (Pubitemid 28122493)
29. Mangia A, Gentile R, Cascavilla I et al. HLA class II favors clearance of HCV infection and progression of the chronic liver damage. J Hepatol 1999 30 6 984-989 (Pubitemid 29278740)
30. Minton E J., Smillie D, Neal K R., Irving W L., Underwood J C., James V, Members of the Trent Hepatitis C Virus Study Group. Association between MHC class II alleles and clearance of circulating hepatitis C virus. J Infect Dis 1998 178 1 39-44 (Pubitemid 28328074)
31. Yenig'n A, Durupinar B. Decreased frequency of the HLA-DRB1*11 allele in patients with chronic hepatitis C virus infection. J Virol 2002 76 4 1787-1789 (Pubitemid 34094626)
32. Zavaglia C, Bortolon C, Ferrioli G et al. HLA typing in chronic type B, D and C hepatitis. J Hepatol 1996 24 6 658-665 (Pubitemid 26226660)
33. Martinetti M, Pacati I, Cuccia M et al. Hierarchy of baby-linked immunogenetic risk factors in the vertical transmission of hepatitis C virus. Int J Immunopathol Pharmacol 2006 19 2 369-378 (Pubitemid 44181959)
34. Yee L J. Host genetic determinants in hepatitis C virus infection. Genes Immun 2004 5 4 237-245 (Pubitemid 38967177)
35. Kikuchi I, Ueda A, Mihara K et al. The effect of HLA alleles on response to interferon therapy in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 1998 10 10 859-863 (Pubitemid 28493263)
36. Sim H, Wojcik J, Margulies M, Wade J A., Heathcote J. Response to interferon therapy: influence of human leucocyte antigen alleles in patients with chronic hepatitis C. J Viral Hepat 1998 5 4 249-253 (Pubitemid 28358228)
37. Asti M, Martinetti M, Zavaglia C et al. Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease. Hepatology 1999 29 4 1272-1279 (Pubitemid 29168765)
38. Renou C, Halfon P, Pol S et al. Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels. Gut 2002 51 4 585-590
39. Kuzushita N, Hayashi N, Moribe T et al. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. Hepatology 1998 27 1 240-244 (Pubitemid 28041560)
40. Haruna Y, Miyamoto T, Yasunami R, Kanda T, Fushimi H, Kotoh K. Human leukocyte antigen DRB1 1302 protects against bile duct damage and portal lymphocyte infiltration in patients with chronic hepatitis C. J Hepatol 2000 32 5 837-842 (Pubitemid 30262745)
41. H'e S, Cacoub P, Renou C et al. Human leukocyte antigen class II alleles may contribute to the severity of hepatitis C virus-related liver disease. J Infect Dis 2002 186 1 106-109 (Pubitemid 34666921)
42. Yasunami R, Miyamoto T, Kanda T. HLA-DRB1 is related to the pathological changes of the liver in chronic hepatitis C. Hepatol Res 1997 7 3-12 (Pubitemid 27316189)
43. Tillmann H L., Chen D F., Trautwein C et al. Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease. Gut 2001 48 5 714-718 (Pubitemid 32378596)
44. Tokushige K, Tsuchiya N, Hasegawa K et al. Influence of TNF gene polymorphism and HLA-DRB1 haplotype in Japanese patients with chronic liver disease caused by HCV. Am J Gastroenterol 2003 98 1 160-166 (Pubitemid 36135185)
45. Fadda L, Borhis G, Ahmed P et al. Peptide antagonism as a mechanism for NK cell activation. Proc Natl Acad Sci U S A 2010 107 22 10160-10165
46. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009 119 7 1745-1754
47. Thio C L., Thomas D L., Karacki P et al. Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J Virol 2003 77 22 12083-12087 (Pubitemid 37345173)
48. Neumann-Haefelin C, Thimme R. Impact of the genetic restriction of virus-specific T-cell responses in hepatitis C virus infection. Genes Immun 2007 8 3 181-192 (Pubitemid 46672051)
49. Thio C L., Gao X, Goedert J J. et al. HLA-Cw*04 and hepatitis C virus persistence. J Virol 2002 76 10 4792-4797 (Pubitemid 34441685)
50. McKiernan S M., Hagan R, Curry M et al. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 2004 40 1 108-114 (Pubitemid 38877575)
51. Dazert E, Neumann-Haefelin C, Bressanelli S et al. Loss of viral fitness and cross-recognition by CD8 + T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J Clin Invest 2009 119 2 376-386
52. Neumann-Haefelin C, Timm J, Schmidt J et al. Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8 + T-cell epitope. Hepatology 2010 51 1 54-62
53. Kim A Y., Kuntzen T, Timm J, Nolan B E., Baca M A., Reyor L L. et al. Spontaneous control of HCV is associated with expression of HLA-B*57 and preservation of targeted epitopes. Gastroenterology 2010 140 2 686-696
54. Kuniholm M H., Kovacs A, Gao X et al. Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. Hepatology 2010 51 5 1514-1522
55. Knapp S, Warshow U, Hegazy D et al. Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology 2010 51 4 1168-1175
56. Romero V, Azocar J, Z''iga J et al. Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in hepatitis C virus infection outcome. Mol Immunol 2008 45 9 2429-2436
57. Khakoo S I., Thio C L., Martin M P. et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004 305 5685 872-874 (Pubitemid 39038423)
58. Parham P. Immunology. NK cells lose their inhibition. Science 2004 305 5685 786-787 (Pubitemid 39038400)
59. Gao X, Jiao Y, Wang L et al. Inhibitory KIR and specific HLA-C gene combinations confer susceptibility to or protection against chronic hepatitis B. Clin Immunol 2010 137 1 139-146
60. Guidotti L G., Ando K, Hobbs M V. et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A 1994 91 9 3764-3768 (Pubitemid 24139512)
61. Guidotti L G., Ishikawa T, Hobbs M V., Matzke B, Schreiber R, Chisari F V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996 4 1 25-36 (Pubitemid 26054933)
62. Höhler T, Kruger A, Gerken G, Schneider P M., Meyer zum B'schenefelde K H., Rittner C. A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 1998 111 3 579-582 (Pubitemid 28160904)
63. Kim Y J., Lee H S., Yoon J H. et al. Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet 2003 12 19 2541-2546 (Pubitemid 37220418)
64. Larrea E, Garcia N, Qian C, Civeira M P., Prieto J. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996 23 2 210-217 (Pubitemid 26045936)
65. Höhler T, Kruger A, Gerken G, Schneider P M., Meyer zum B'schenfelde K H., Rittner C. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol 1998 54 3 173-177 (Pubitemid 28102806)
66. Constantini P K., Wawrzynowicz-Syczewska M, Clare M et al. Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy. Liver 2002 22 5 404-412 (Pubitemid 35331401)
67. Rosen H R., McHutchison J G., Conrad A J. et al. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol 2002 97 3 714-720 (Pubitemid 34245903)
68. Thio C L., Goedert J J., Mosbruger T et al. An analysis of tumor necrosis factor alpha gene polymorphisms and haplotypes with natural clearance of hepatitis C virus infection. Genes Immun 2004 5 4 294-300 (Pubitemid 38961163)
69. Yee L J., Tang J, Gibson A W., Kimberly R, Van Leeuwen D J., Kaslow R A. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001 33 3 708-712 (Pubitemid 32185234)
70. Schiemann U, Glas J, Török P et al. Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism. Digestion 2003 68 1 1-4 (Pubitemid 37256039)
71. Yu M L., Dai C Y., Chiu C C. et al. Tumor necrosis factor alpha promoter polymorphisms at position -308 in Taiwanese chronic hepatitis C patients treated with interferon-alpha. Antiviral Res 2003 59 1 35-40
72. Yee L J., Tang J, Herrera J, Kaslow R A., van Leeuwen D J. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000 1 6 386-390
73. Bayley J P., Ottenhoff T H., Verweij C L. Is there a future for TNF promoter polymorphisms? Genes Immun 2004 5 5 315-329 (Pubitemid 39139757)
74. Frese M, Schw'rzle V, Barth K et al. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002 35 3 694-703 (Pubitemid 34183976)
75. Huang Y, Yang H, Borg B B. et al. A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci U S A 2007 104 3 985-990 (Pubitemid 46154723)
76. Yin L M., Zhu W F., Wei L et al. Association of interleukin-12 p40 gene 3-untranslated region polymorphism and outcome of HCV infection. World J Gastroenterol 2004 10 16 2330-2333 (Pubitemid 39157754)
77. Houldsworth A, Metzner M, Rossol S et al. Polymorphisms in the IL-12B gene and outcome of HCV infection. J Interferon Cytokine Res 2005 25 5 271-276 (Pubitemid 40664424)
78. Hegazy D, Thurairajah P, Metzner M et al. Interleukin 12B gene polymorphism and apparent resistance to hepatitis C virus infection. Clin Exp Immunol 2008 152 3 538-541 (Pubitemid 351661506)
79. Mueller T, Mas-Marques A, Sarrazin C et al. Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection. J Hepatol 2004 41 4 652-658 (Pubitemid 39297802)
80. Mosbruger T L., Duggal P, Goedert J J. et al. Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis 2010 201 9 1371-1380
81. An P, Thio C L., Kirk G D., Donfield S, Goedert J J., Winkler C A. Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C virus clearance. J Infect Dis 2008 198 8 1159-1165
82. Edwards-Smith C J., Jonsson J R., Purdie D M., Bansal A, Shorthouse C, Powell E E. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999 30 2 526-530 (Pubitemid 29357520)
83. Knapp S, Hennig B J., Frodsham A J. et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 2003 55 6 362-369 (Pubitemid 37255487)
84. Vidigal P G., Germer J J., Zein N N. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol 2002 36 2 271-277 (Pubitemid 34146435)
85. Eskdale J, Gallagher G, Verweij C L., Keijsers V, Westendorp R G., Huizinga T W. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A 1998 95 16 9465-9470 (Pubitemid 28506254)
86. Nelson D R., Lauwers G Y., Lau J Y., Davis G L. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000 118 4 655-660 (Pubitemid 30171614)
87. Frodsham A J., Zhang L, Dumpis U et al. Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. Proc Natl Acad Sci U S A 2006 103 24 9148-9153 (Pubitemid 43902547)
88. Kotenko S V., Gallagher G, Baurin V V. et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003 4 1 69-77 (Pubitemid 36109115)
89. Barrett S, Collins M, Kenny C, Ryan E, Keane C O., Crowe J. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol 2003 71 2 212-218 (Pubitemid 37048464)
90. Gale M Jr, Foy E M. Evasion of intracellular host defence by hepatitis C virus. Nature 2005 436 7053 939-945 (Pubitemid 41191669)
91. Dunn C, Peppa D, Khanna P et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009 137 4 1289-1300
92. Knapp S, Yee L J., Frodsham A J. et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun 2003 4 6 411-419 (Pubitemid 38967606)
93. Hijikata M, Mishiro S, Miyamoto C, Furuichi Y, Hashimoto M, Ohta Y. Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analyzing two SNP sites (-123 and -88) in vivo and in vitro. Intervirology 2001 44 6 379-382 (Pubitemid 34114189)
94. Ge D, Fellay J, Thompson A J. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009 461 7262 399-401
95. Rauch A, Kutalik Z, Descombes P et al, Swiss Hepatitis C Cohort Study Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010 138 4 1338-1345, 1345, e1-e7
96. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009 41 10 1100-1104
97. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009 41 10 1105-1109
98. Thomas D L., Thio C L., Martin M P. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009 461 7265 798-801
99. Honda M, Sakai A, Yamashita T et al, Hokuriku Liver Study Group. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010 139 2 499-509
100. Kamatani Y, Wattanapokayakit S, Ochi H et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009 41 5 591-595
101. Zhang H, Zhai Y, Hu Z et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010 42 9 755-758
102. Huang H, Shiffman M L., Friedman S et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007 46 2 297-306 (Pubitemid 47344763)
103. Wright M, Goldin R, Hellier S et al. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 2003 52 8 1206-1210 (Pubitemid 36877437)
104. Papatheodoridis G V., Papakonstantinou E, Andrioti E et al. Thrombotic risk factors and extent liver fibrosis in chronic viral hepatitis. Gut 2003 52 3 404-409 (Pubitemid 36250062)
105. Anstee Q M., Goldin R D., Wright M et al. Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. J Thromb Haemost 2008 6 8 1336-1343 (Pubitemid 352016314)
106. Perelygin A A., Scherbik S V., Zhulin I B. et al. Positional cloning of the murine flavivirus resistance gene. Proc Natl Acad Sci USA 2002 99 14 9322-9327 (Pubitemid 34764612)